Granules India Limited Received ANDA Approval for Sildenafil for Oral Suspension 

December 3, 2023
  • Granules has a total of 63 ANDA approvals from the US FDA (61 final and 2 tentative approvals)
  • Sildenafil for Oral Suspension is indicated for the treatment of pulmonary arterial hypertension (PAH) to improve exercise ability and delay clinical worsening.

India

healthysoch

Hyderabad/Chandigarh, December 03, 2023:

Granules India Limited announced today that the US Food & Drug Administration (US FDA) has approved its Abbreviated New Drug Application (ANDA), filed by Granules Pharmaceuticals, Inc. (GPI), a wholly owned foreign subsidiary of the company, for Sildenafil for Oral Suspension, 10 mg/mL. It is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Revatio for Oral Suspension, 10mg/ml, of Viatris Specialty LLC.

Sildenafil for Oral Suspension is indicated for the treatment of pulmonary arterial hypertension (PAH) (World Health Organization [WHO] Group I) in adults to improve exercise ability and delay clinical worsening.

Granules now has a total of 63 ANDA approvals from the US FDA (61 final approvals and 2 tentative approvals). The current annual U.S. market for Sildenafil for Oral Suspension is approximately $43 million, according to MAT Sep 2023, IQVIA/IMS Health.

healthysoch

Stay informed with the latest news from HealthySoch. Sign up today for exclusive insights and updates!

We promise we never spam!

Leave a Reply

Your email address will not be published.

Columnists

HealthySoch

Don't Miss

ZEISS SFL 30, the newest, lightest and most compact binoculars Launched

ZEISS, a 177-year-old heritage brand in the lens manufacturing business

Indira IVF opens its 93rd state-of-the-art infertility treatment clinic in Ujjain

“The Ujjain centre is the 10th facility to be added